%0 Journal Article
%T Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review.
%A Nativi-Nicolau J
%A Yilmaz A
%A Dasgupta N
%A Macey R
%A Cochrane J
%A Peatman J
%A Summers C
%A Luth J
%A Zolty R
%J J Comp Eff Res
%V 13
%N 7
%D 2024 Jul 13
%M 38869839
%F 2.04
%R 10.57264/cer-2023-0158
%X Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. Objective: To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. Method: A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Results: Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.